CBG 166
Alternative Names: CBG-166Latest Information Update: 19 Jul 2024
At a glance
- Originator Carbiogene Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 17 Jun 2024 Preclinical trials in Liver cancer in China (IV), before June 2024
- 17 Jun 2024 Zhejiang University in collaboration with Carbiogene Therapeutics plan phase I trial in Liver cancer (Second-line therapy and greater, Late-stage disease) in July 2024 (IV) (NCT06461624)